Romulus K. Brazzell - 31 May 2024 Form 4 Insider Report for KALA BIO, Inc. (KALA)

Role
Head of Research and Development and Chief Medical Officer
Signature
/s/ Mary Reumuth, Attorney-in-Fact
Issuer symbol
KALA
Transactions as of
31 May 2024
Net transactions value
-$12,192
Form type
4
Filing time
03 Jun 2024, 20:00:09 UTC
Previous filing
05 Jan 2024
Next filing
27 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Sale $12,192 -2,002 -2.2% $6.09 89,471 31 May 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 Includes 75,743 unvested RSUs.

Remarks:

Head of Research and Development and Chief Medical Officer